Actrapid

Actrapid Caution For Usage

Manufacturer:

Novo Nordisk

Distributor:

Zuellig Pharma
Full Prescribing Info
Caution For Usage
For intravenous use, infusion systems with Actrapid at concentrations from 0.05 IU/mL to 1.0 IU/mL insulin human in the infusion fluids: 0.9% sodium chloride, 5% dextrose and 10% dextrose inclusive 40 mmol/L potassium chloride, using polypropylene infusion bags, are stable at room temperature for 24 hours. Although stable over time, a certain amount of insulin will initially be absorbed to the material of the infusion bag. Monitoring of blood glucose is necessary during the infusion.
Cartridges and Pens should only be used in combination with products that are compatible with them and allow the cartridge or flexpen to function safely and effectively.
Needles and Actrapid Penfill, Actrapid Flexpen must not be shared. The container must not be refilled.
Insulin preparations which have been frozen must not be used.
Insulin solutions should not be used if they do not appear clear and colourless.
Actrapid should not be used in insulin pumps for continuous subcutaneous insulin infusion. The patient should be advised to discard the needle after each injection.
In case of emergency in current Actrapid users (hospitalisation or insulin pen malfunction), Actrapid can be withdrawn with an U100 insulin syringe from the cartridge or from the Flexpen.
Incompatibilities: Insulin products should only be added to compounds with which it is known to be compatible.
Medicinal products added to the insulin solution may cause degradation of the insulin, e.g. if the medicinal products contain thiols or sulphites.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in